FIRST-LINE TAGRISSO® IN
ADVANCED EGFRm NSCLC

GROUNDBREAKING PFS AND
OVERALL SURVIVAL

38.6 vs 31.8

months median OS
for gefitinib/erlotinib*
(HR=0.799; P=0.0462) in the FLAURA study1

IN THE FLAURA STUDY

Progression-free survival was the primary endpoint. Overall Survival was a prespecified secondary endpoint.

Median OS for TAGRISSO was 38.6 months (95% CI: 34.5, 41.8) vs 31.8 months for gefitinib/erlotinib (95% CI: 26.6, 36.0); the HR=0.799 for OS was statistically significant (95.05% CI: 0.641, 0.997; P=0.0462).

TAGRISSO AS MONOTHERAPY IS INDICATED FOR:

  • the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
  • the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

Reference: 1. AstraZeneca Pharmaceuticals. TAGRISSO® (osimertinib). Summary of Product Characteristics, 2020.